Alprazolam for depression

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Van Marwijk, Harm ^a   Bax, A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DATA EXTRACTION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; OUTPATIENT; PRIMARY MEDICAL CARE; PUBLISHING; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 44949134036     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007139     Document Type: Review

References (26)

1. APA 1980 American Psychiatric Association. Diagnostic and statisticalmanual of mental disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
2. APA 1995 American Psychiatric Association. Diagnostic and Statistical Manual, Fourth edition, International version. Washington, DC: American Psychiatric Association, 1995.
3. Birkenhager 1995 Birkenhager TK, Moleman P, Nolen WA. Benzodiazepines for depression? A review of the literature. International Clinical Psychopharmacology 1995;10:181-93. [MEDLINE: 8675792].
4. Committee 1980 Committee on the review of medicines. Systematic review of the benzodiazepines: guidelines for the data sheets for diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazapam, flurazepam. BMJ 1980;1:910-2.
5. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 318].
6. Feighner 1972 Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26(1):57-63. [MEDLINE: 295].
7. Furukawa 2002 Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine formajor depression. Cochrane Database of Systematic Reviews 2002, Issue 1.
8. Furukawa 2006 Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
9. Guy 1976 Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.
10. Hamilton 1960 Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62. [MEDLINE: 319].
11. Hansen 2004 Hansen DG, Vach W, Rosholm JU, Sondergaard J, Gram LF, Kragstrup J. Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Family Practice 2004;21:623-9. [MEDLINE: 15520034].
12. Higgins 2006 Higgins JPT, Greene S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [Updated September 2006]. Chichester, UK: John Whiley & Sons, 2006.
13. Jonas 1993 Jonas JM, Cohon MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic and depression: a review of the literature. Journal of Clinical Psychiatry 1993;54:S25-45. [MEDLINE: 8262888].
14. Lawrenson 2000 Lawrenson RA, Tyrer F, Newson RB, Farmer RD. The treatment of depression in UK general practice: selective serotonin inhibitors and tricyclic antidepressants compared. Journal of Affective Disorders 2000;59:149-57. [MEDLINE: 10837883].
15. Moher 1996 Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. International Journal of Technology Assessment in Health Care 1996;12(2):195-208. [MEDLINE: 287].
16. Moncrieff 2003 Moncrieff J, Wessely F, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews 2004, Issue CD 003012.Art. No.: CD003012. DOI:10.1002/14651858. CD003012.pub2.
17. Montgomery 1979 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9. [MEDLINE: 292].
18. Murphy 1990 Murphy JM. Depression in the community: findings from the Stirling County Study. Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie 1990;35(5):390-6. [MEDLINE: 286].
19. NICE 2004 National Institute for Clinical Excellence (NICE). Depression. Management of depression in primary and secondary care. Clinical Guideline 23. London: National Institute for Clinical Excellence, 2004.
20. Petty 1995 Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: does GABA play a role in depression?. Biological Psychiatry 1995;38(9):578-91. [MEDLINE: 294].
21. Rijswijk 2007 van Rijswijk E, Borghuis M, van de Lisdonk E, Zitman F, van Weel C. Treatment of mental health problems in general practice: a survey of psychotropics prescribed and other treatments provided. International Journal of Clinical Pharmacology and Therapeutics 2007;45(1):23-9.
22. Schweizer 1998 Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatrica Scandinavica, Supplementum 1998;393:95-101. [MEDLINE: 285].
23. Sethy 1982 Sethy VH, Hodges DH Jr. Alprazolam in a biochemical model of depression. Biochemical Pharmacology 1982;31(19):3155-7. [MEDLINE: 290].
24. van Marwijk 2003 van Marwijk HW, Grundmeijer HGLM, Bijl D, et al. Dutch College of General Practitioners Guideline Depression, first revision. Huisarts en Wetenschap 2003;46:614-23.
25. Van Tulder 1999 van Tulder MW, Assendelft WJJ, Koes BW, Bouter LM. Methodologic guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997;22:2323-30.
26. WHO 2003 World Health Organisation. International classification of diseases (ICD-10). Geneva: World Health Organisation, 2003.